The US Senate inserted a revised Biosecure Act into the National Defense Authorization Act, voting to restrict federal funding and contracting with biotechnology companies deemed a national security risk. BioCentury and other outlets report the amendment narrows company naming but keeps the core prohibition mechanisms that could limit partnerships and supply chains with certain foreign firms. The measure departs from last year’s House‑passed version by avoiding explicit company listings, a change intended to broaden support in the Senate. Industry groups and academic researchers have warned the policy could disrupt global collaboration and specialized manufacturing capacity; lawmakers argue the changes protect critical supply lines and guard against foreign‑state influence in strategic biotechnologies.